{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:27:13Z","timestamp":1772242033637,"version":"3.50.1"},"reference-count":46,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Patients with type 2 diabetes (T2D) have a high risk for developing heart failure (HF), which is associated with poor prognosis. Fenofibrate may reduce HF events through multiple mechanisms. We sought to study the effect of fenofibrate (vs. placebo) in HF outcomes among patients with T2D receiving simvastatin enrolled in the Action to Control Cardiovascular Risk in Diabetes lipid trial (ACCORD Lipid).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>We used Cox regression analysis with background glucose-lowering strategy as the stratification variable. The median follow-up was 4.7 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 5,518 patients were included. Median age was 62 years, and 31% were women. Prior HF history was present in 5% of the patients. The composite outcome of HF hospitalization or cardiovascular death occurred in 190 (6.9%) patients in the fenofibrate group vs. 228 (8.3%) in the placebo group: HR 0.82, 95% CI 0.68\u20131.00 (P = 0.048). The beneficial effect of fenofibrate to reduce HF hospitalizations or cardiovascular death was present among patients receiving standard glucose-lowering strategy, HR 0.64, 95% CI 0.48\u20130.85, and not among patients receiving intensive glucose-lowering strategy, HR 1.02, 95% CI 0.79\u20131.33 (Pinteraction = 0.017). A similar pattern was observed for HF hospitalizations alone. The effect of fenofibrate on blood lipids was not influenced by background glucose-lowering therapy in a clinically important manner. Fenofibrate caused more transient worsening estimated glomerular filtration rate (eGFR) events but slowed long-term eGFR decline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In patients with T2D treated with simvastatin, fenofibrate reduced the composite of HF hospitalizations or cardiovascular mortality, an effect that was seen predominantly in patients with standard background glucose-lowering therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc21-1977","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T16:48:14Z","timestamp":1648054094000},"page":"1584-1591","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":34,"title":["Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD"],"prefix":"10.2337","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[{"name":"1INSERM, Centre d'Investigations Cliniques - Plurith\u00e9matique 14-33, Universit\u00e9 de Lorraine, and INSERM U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France"},{"name":"2Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"given":"Francisco","family":"Vasques-N\u00f3voa","sequence":"additional","affiliation":[{"name":"2Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"given":"Diana","family":"Ferr\u00e3o","sequence":"additional","affiliation":[{"name":"2Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"given":"Francisca","family":"Saraiva","sequence":"additional","affiliation":[{"name":"2Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"given":"In\u00eas","family":"Falc\u00e3o-Pires","sequence":"additional","affiliation":[{"name":"2Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8173-8255","authenticated-orcid":false,"given":"Jo\u00e3o S\u00e9rgio","family":"Neves","sequence":"additional","affiliation":[{"name":"2Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal"},{"name":"3Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-8330","authenticated-orcid":false,"given":"Abhinav","family":"Sharma","sequence":"additional","affiliation":[{"name":"4DREAM-CV Lab, Division of Cardiology, McGill University Health Centre, Montreal, Canada"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"1INSERM, Centre d'Investigations Cliniques - Plurith\u00e9matique 14-33, Universit\u00e9 de Lorraine, and INSERM U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"1INSERM, Centre d'Investigations Cliniques - Plurith\u00e9matique 14-33, Universit\u00e9 de Lorraine, and INSERM U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France"}]},{"given":"Adelino","family":"Leite-Moreira","sequence":"additional","affiliation":[{"name":"2Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal"}]}],"member":"1167","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"2022070714525207200_B1","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"2022070714525207200_B2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jchf.2014.08.004","article-title":"Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure","volume":"3","author":"Dei Cas","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2022070714525207200_B3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"2022070714525207200_B4","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"2022070714525207200_B5","doi-asserted-by":"crossref","first-page":"e000137","DOI":"10.1136\/bmjdrc-2015-000137","article-title":"Intensity of statin therapy and new hospitalizations for heart failure in patients with type 2 diabetes","volume":"3","author":"Kishimoto","year":"2015","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2022070714525207200_B6","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"2022070714525207200_B7","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.2337\/dc20-1533","article-title":"Fenofibrate use is associated with lower mortality and fewer cardiovascular events in patients with diabetes: results of 10,114 patients from the Korean National Health Insurance Service cohort","volume":"44","author":"Jo","year":"2021","journal-title":"Diabetes Care"},{"key":"2022070714525207200_B8","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"2022070714525207200_B9","doi-asserted-by":"crossref","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods","volume":"99","author":"Buse","year":"2007","journal-title":"Am J Cardiol"},{"key":"2022070714525207200_B10","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"2022070714525207200_B11","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ejhf.1146","article-title":"Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes","volume":"20","author":"Cosmi","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2022070714525207200_B12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ejhf.1535","article-title":"Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction","volume":"21","author":"Shen","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022070714525207200_B13","doi-asserted-by":"crossref","first-page":"l7078","DOI":"10.1136\/bmj.l7078","article-title":"Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses","volume":"368","author":"Wallach","year":"2020","journal-title":"BMJ"},{"key":"2022070714525207200_B14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2007.03.113","article-title":"Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice","volume":"133","author":"Lee","year":"2007","journal-title":"Gastroenterology"},{"key":"2022070714525207200_B15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2213-8587(18)30029-9","article-title":"Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study","volume":"6","author":"Waldman","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022070714525207200_B16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2288-3-26","article-title":"Design, analysis and presentation of factorial randomised controlled trials","volume":"3","author":"Montgomery","year":"2003","journal-title":"BMC Med Res Methodol"},{"key":"2022070714525207200_B17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"2022070714525207200_B18","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/dom.14283","article-title":"Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HFDM) in patients in the ACCORD trial","volume":"23","author":"Elharram","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2022070714525207200_B19","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1037\/0022-3514.51.6.1173","article-title":"The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations","volume":"51","author":"Baron","year":"1986","journal-title":"J Pers Soc Psychol"},{"key":"2022070714525207200_B20","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc21-S006","article-title":"6. Glycemic targets: Standards of Medical Care in Diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"2022070714525207200_B21","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"2022070714525207200_B22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J Med Chem"},{"key":"2022070714525207200_B23","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s00296-012-2613-z","article-title":"The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study","volume":"33","author":"Shirinsky","year":"2013","journal-title":"Rheumatol Int"},{"key":"2022070714525207200_B24","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2337\/diacare.28.6.1419","article-title":"Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia","volume":"28","author":"Koh","year":"2005","journal-title":"Diabetes Care"},{"key":"2022070714525207200_B25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022070714525207200_B26","doi-asserted-by":"crossref","first-page":"e005897","DOI":"10.1161\/CIRCHEARTFAILURE.118.005897","article-title":"Proteomic bioprofiles and mechanistic pathways of progression to heart failure","volume":"12","author":"Ferreira","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2022070714525207200_B27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jchf.2019.11.005","article-title":"Distinct pathological pathways in patients with heart failure and diabetes","volume":"8","author":"Tromp","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2022070714525207200_B28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12933-021-01357-9","article-title":"Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial","volume":"20","author":"Verdonschot","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2022070714525207200_B29","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/cvr\/cvq376","article-title":"Sirt1 acts in association with PPAR\u03b1 to protect the heart from hypertrophy, metabolic dysregulation, and inflammation","volume":"90","author":"Planavila","year":"2011","journal-title":"Cardiovasc Res"},{"key":"2022070714525207200_B30","doi-asserted-by":"crossref","first-page":"E1519","DOI":"10.3390\/jcm8101519","article-title":"Autophagy and inflammasome activation in dilated cardiomyopathy","volume":"8","author":"Caragnano","year":"2019","journal-title":"J Clin Med"},{"key":"2022070714525207200_B31","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/jcmm.12312","article-title":"Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice","volume":"18","author":"Wang","year":"2014","journal-title":"J Cell Mol Med"},{"key":"2022070714525207200_B32","doi-asserted-by":"crossref","first-page":"e007197","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","article-title":"Cardioprotective effects of sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors","volume":"13","author":"Packer","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2022070714525207200_B33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.cmet.2014.06.010","article-title":"The PPAR\u03b1-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway","volume":"20","author":"Vernia","year":"2014","journal-title":"Cell Metab"},{"key":"2022070714525207200_B34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2022070714525207200_B35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022070714525207200_B36","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"2022070714525207200_B37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","article-title":"Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)","volume":"45","author":"Ansquer","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2022070714525207200_B38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"2022070714525207200_B39","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants","volume":"35","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care"},{"key":"2022070714525207200_B40","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2215\/CJN.00370119","article-title":"The association of fenofibrate with kidney tubular injury in a subgroup of participants in the ACCORD trial","volume":"14","author":"Chauhan","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022070714525207200_B41","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022070714525207200_B42","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","article-title":"The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"2022070714525207200_B43","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"2022070714525207200_B44","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/db19-0973","article-title":"PPARA polymorphism influences the cardiovascular benefit of fenofibrate in type 2 diabetes: findings from ACCORD-Lipid","volume":"69","author":"Morieri","year":"2020","journal-title":"Diabetes"},{"key":"2022070714525207200_B45","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"key":"2022070714525207200_B46","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/45\/7\/1584\/685190\/dc211977.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/45\/7\/1584\/685190\/dc211977.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T10:54:10Z","timestamp":1657191250000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/45\/7\/1584\/144882\/Fenofibrate-and-Heart-Failure-Outcomes-in-Patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,3,23]]},"published-print":{"date-parts":[[2022,7,7]]}},"URL":"https:\/\/doi.org\/10.2337\/dc21-1977","relation":{"has-preprint":[{"id-type":"doi","id":"10.2337\/figshare.19278446.v1","asserted-by":"object"},{"id-type":"doi","id":"10.2337\/figshare.19278446","asserted-by":"object"}]},"ISSN":["0149-5992"],"issn-type":[{"value":"0149-5992","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,23]]}}}